ATE419006T1 - Multivalenter dengue-virus impfstoff - Google Patents

Multivalenter dengue-virus impfstoff

Info

Publication number
ATE419006T1
ATE419006T1 AT00919748T AT00919748T ATE419006T1 AT E419006 T1 ATE419006 T1 AT E419006T1 AT 00919748 T AT00919748 T AT 00919748T AT 00919748 T AT00919748 T AT 00919748T AT E419006 T1 ATE419006 T1 AT E419006T1
Authority
AT
Austria
Prior art keywords
dengue
virus
dengue virus
virus vaccine
attenuated
Prior art date
Application number
AT00919748T
Other languages
English (en)
Inventor
Kenneth Eckels
Joseph Putnak
Doria Dubois
Bruce Innis
Charles Hoke
Sun Wellington
Kanesa-Thasan Niranjan
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE419006T1 publication Critical patent/ATE419006T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00919748T 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff ATE419006T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12631399P 1999-03-26 1999-03-26
US18172400P 2000-02-11 2000-02-11

Publications (1)

Publication Number Publication Date
ATE419006T1 true ATE419006T1 (de) 2009-01-15

Family

ID=26824502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919748T ATE419006T1 (de) 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff

Country Status (12)

Country Link
US (2) US6638514B1 (de)
EP (1) EP1165127B1 (de)
JP (1) JP2002540168A (de)
KR (1) KR100721745B1 (de)
CN (1) CN1191092C (de)
AT (1) ATE419006T1 (de)
AU (1) AU779280B2 (de)
CA (1) CA2368674A1 (de)
DE (1) DE60041250D1 (de)
ES (1) ES2322327T3 (de)
MX (1) MXPA01009683A (de)
WO (1) WO2000057907A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100721745B1 (ko) * 1999-03-26 2007-05-25 왈터 리드 아미 인스티튜트 오브 리써치 다가 뎅기 바이러스 백신
ES2523168T3 (es) 2001-05-22 2014-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
WO2006134443A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 2 attenuated strain
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
UY31437A1 (es) * 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
EP2376923A4 (de) * 2008-12-22 2012-08-15 Children S Res Inst Verfahren für den nachweis von sepsis
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2438198A4 (de) * 2009-06-01 2014-05-14 Inviragen Inc Zusammensetzungen und verfahren zur verabreichung von impfstoffen gegen den dengue-virus
DK2384761T3 (da) * 2010-05-07 2013-12-09 Deutsches Krebsforsch Modificeret gnaverparvovirus, som er i stand til formering og spredning i humane gliomer
AU2014281713A1 (en) * 2013-06-21 2015-11-12 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10449243B2 (en) 2014-12-22 2019-10-22 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
EP3316897A4 (de) 2015-07-02 2019-03-13 Primevax Immuno-Oncology, Inc. Zusammensetzungen und verfahren zur kombinationstherapie mit dem dengue-virus und dendritischen zellen
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
WO2018093907A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
EP4205760A1 (de) * 2017-03-08 2023-07-05 University of Georgia Research Foundation, Inc. Verfahren und zusammensetzungen in zusammenhang mit erhöhter virusproduktion
SG11201912163WA (en) * 2017-06-15 2020-01-30 Primevax Immuno Oncology Inc Compositions and methods for cancer therapy with dengue virus and dendritic cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181792A (ja) * 1992-06-05 1994-07-05 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法、およびそれに用いる組み換えウイルス
AU676340B2 (en) 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
CA2269213A1 (en) * 1996-10-28 1998-05-07 The University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral rna
KR100721745B1 (ko) * 1999-03-26 2007-05-25 왈터 리드 아미 인스티튜트 오브 리써치 다가 뎅기 바이러스 백신

Also Published As

Publication number Publication date
EP1165127A2 (de) 2002-01-02
WO2000057907A3 (en) 2001-04-12
WO2000057907A2 (en) 2000-10-05
US6638514B1 (en) 2003-10-28
ES2322327T3 (es) 2009-06-19
EP1165127B1 (de) 2008-12-31
US7217418B2 (en) 2007-05-15
AU779280B2 (en) 2005-01-13
DE60041250D1 (de) 2009-02-12
MXPA01009683A (es) 2003-06-24
KR100721745B1 (ko) 2007-05-25
US20070087015A1 (en) 2007-04-19
CA2368674A1 (en) 2000-10-05
AU4038200A (en) 2000-10-16
KR20020008136A (ko) 2002-01-29
CN1191092C (zh) 2005-03-02
JP2002540168A (ja) 2002-11-26
CN1351502A (zh) 2002-05-29
WO2000057907A9 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
ATE419006T1 (de) Multivalenter dengue-virus impfstoff
Tuiskunen Bäck et al. Dengue viruses–an overview
Ghosh et al. Dengue vaccines: challenges, development, current status and prospects
Nedjadi et al. Tackling dengue fever: Current status and challenges
PH12018502175A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
IL196815A0 (en) Hepatitis c virus inhibitors
MX338530B (es) Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
MX2009012299A (es) Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue.
BRPI0822335A2 (pt) inibidores do vírus da hepatite c
PE20020474A1 (es) Compuestos peptidomimeticos como inhibidores de la serina proteasa ns3 del virus de hepatitis c
NO20044897L (no) Hepatitt C virus inhibitorer
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
MY180698A (en) Immunization protocol against the 4 dengue serotypes
PL373398A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
EP2448410A4 (de) Behandlung und vorbeugung von infektionen mit dem dengue-virus
DE69940769D1 (de) Orale flüssige zusammensetzungen
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
MY169275A (en) Method of immunization against the four serotypes of dengue
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
JP2002540168A5 (de)
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
JP2016504315A5 (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties